Trial Profile
A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2022 Planned End Date changed from 1 Nov 2022 to 30 Apr 2024.
- 22 Jun 2022 Planned primary completion date changed from 1 Nov 2022 to 31 Mar 2024.
- 15 Jan 2021 Planned End Date changed from 1 Nov 2020 to 1 Nov 2022.